REG - Scancell Hlds - Notice of Final Results

Scancell HoldingsAnnouncement

18/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240918:nRSR5943Ea&default-theme=true

RNS Number : 5943E  Scancell Holdings Plc  18 September 2024

18 September 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Notice of Final Results

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, will announce its results for the year ended 30 April
2024 on Tuesday 24 September 2024.

 

Professor Lindy Durrant, Chief Executive Officer, and Sath Nirmalananthan,
Chief Financial Officer, will host a virtual analyst briefing at 13:00 BST on
the day of the results. There will also be a live webcast and conference call
with a Q&A session. The webcast will be shared on the Investor Relations
section of the Company's website at https://scancell.co.uk/
(https://scancell.co.uk/) .

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                    +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)             +44 (0) 20 7886 2500
 Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)
                                                                          +44 (0) 20 3705 9330

 WG Partners LLP (Joint Broker)

 David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby

 ICR Consilium                                                            +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville                            scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or
drugs. The Company's approaches are that vaccines (ImmunoBody® and
Moditope®) use unique receptors to target antigens to activated antigen
presenting cells whereas its mAb portfolio targets glycans or sugars that are
added onto proteins and / or lipids (GlyMab®) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab®).

 

For further information about Scancell, please
visit: https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBCGDCCDBDGSR